Revvity RVTY Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Segment revenue by Business | ||||||
| Diagnostics | $349.27M-10.5% | $390.07M+9.5% | $356.13M+0.5% | $354.39M+9.3% | $324.37M-8.5% | |
| Life Sciences | $361.85M-5.3% | $381.99M+11.4% | $342.82M-6.3% | $365.9M+7.5% | $340.4M-9.2% | |
| Segment Cost of Revenue by Business | ||||||
| Diagnostics | $156.75M-14.6% | $183.64M+15.6% | $158.9M+1.8% | $156.04M+15.4% | $135.19M-12.4% | |
| Life Sciences | $131.57M-0.3% | $131.97M+1.5% | $129.98M-3.7% | $135.03M+13.2% | $119.32M-5.8% | |
| Segment operating income by Business | ||||||
| Diagnostics | $76.12M-16.7% | $91.35M+2.2% | $89.38M-0.1% | $89.42M+20.8% | $74.02M-18.8% | |
| Life Sciences | $103.98M-23.6% | $136.03M+34.6% | $101.05M-12.5% | $115.47M+9.2% | $105.71M-23.5% | |
| Segment research and development expenses by Business | ||||||
| Diagnostics | $26.21M-13.7% | $30.38M+31.3% | $23.13M-6.7% | $24.8M-1.9% | $25.27M+10.8% | |
| Life Sciences | $31.62M+14.0% | $27.74M+0.5% | $27.61M-2.8% | $28.42M+0.5% | $28.27M+7.9% | |
| Segment Selling, general and administrative expenses by Business | ||||||
| Diagnostics | $90.19M+6.5% | $84.69M0.0% | $84.72M+0.7% | $84.13M-6.4% | $89.89M+4.1% | |
| Life Sciences | $94.67M+9.8% | $86.25M+2.4% | $84.19M-3.2% | $86.99M-0.1% | $87.09M+4.0% | |
| Restructuring and Other Costs (Income) by Business | ||||||
| Diagnostics | $7.55M— | —— | —— | —— | $135K-95.7% | |
| Life Sciences | $3.23M— | —— | —— | —— | $2.53M+123% | |
| Foreign currency translation by Business | ||||||
| Diagnostics | -$9.83M-370% | $3.63M— | $0-100% | $30.78M+116% | $14.24M— | |
| Life Sciences | -$24.95M-370% | $9.23M— | $0-100% | $72.72M+116% | $33.63M+150% | |
| Goodwill by Business | ||||||
| Diagnostics | $1.86B-0.5% | $1.87B-4.8% | $1.96B-0.2% | $1.97B+1.6% | $1.94B+0.7% | |
| Life Sciences | $4.75B+0.1% | $4.74B+2.3% | $4.64B-0.2% | $4.65B+1.6% | $4.58B+0.7% | |
| Goodwill, Acquisition by Business | ||||||
| Diagnostics | $0— | —— | —— | —— | —— | |
| Life Sciences | $32.04M— | —— | —— | —— | —— | |
| Depreciation by Business | ||||||
| Diagnostics | $9.56M+0.7% | $9.49M+8.1% | $8.79M+6.1% | $8.28M+20.9% | $6.85M-40.6% | |
| Life Sciences | $9.91M+6.5% | $9.3M+9.9% | $8.46M-1.1% | $8.55M+19.0% | $7.19M+42.0% | |
| Lease Abandonment Charges Included In Restructuring and Other Costs by Business | ||||||
| Diagnostics | $1.2M+500% | $200K0.0% | $200K0.0% | $200K0.0% | $200K— | |
| Life Sciences | $1.3M-16.1% | $1.55M0.0% | $1.55M0.0% | $1.55M0.0% | $1.55M— | |
| Segment revenue by Geography | ||||||
| Americas | $315.99M-1.4% | $320.48M+4.3% | $307.28M-5.0% | $323.58M+6.2% | $304.63M-4.4% | |
| Asia | $172.08M-19.7% | $214.42M+13.3% | $189.28M-2.0% | $193.07M+8.3% | $178.34M-16.4% | |
| Europe | $223.05M-6.0% | $237.16M+17.2% | $202.4M-0.6% | $203.63M+12.0% | $181.79M-7.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Revvity break its business down?
- Revvity (RVTY) reports segment revenue by business across 2 parts — Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Revvity's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Revvity's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
